

Hugh S Griffith Chief Executive Officer T: +44 (0) 131 248 3660 E: info@nucanabiomed.com W: www.nucanabiomed.com

Scotland's life sciences sector champions revealed

The prestigious Scottish Enterprise Life Sciences Awards 2013 recognise the success and achievements of Scotland's internationally renowned life sciences sector in areas including innovation, investment, community engagement and collaboration

The winners of the prestigious Scottish Enterprise Life Sciences Awards 2013 have been revealed.

Held at the Edinburgh International Conference Centre last night, the annual awards ceremony was attended by over 700 people from the global life sciences community.

The awards recognise the success and achievements of Scotland's internationally renowned life sciences sector in areas including innovation, investment, community engagement and collaboration.

The awards also focus on the ongoing work of Scottish Enterprise and its partners to grow and develop a sustainable, globally competitive life sciences sector in Scotland.

Scotland's life sciences industry already contributes more than £3 billion a year to the Scottish economy with over 650 organisations employing in excess of 32,000 people. It is globally recognised for its high levels of innovation – translating ideas and research into novel treatments and world-leading therapies.

Congratulating the winners, Rhona Allison, Senior Director of Life Sciences at Scottish Enterprise said: "The quality of candidates for these awards continues to go from strength to strength with each successive year and is testament to Scotland's reputation as an international hub of life sciences expertise.

"Our three new award categories in investment, collaboration and community engagement reflect the importance of these themes in Scotland's industry-led life sciences strategy. Furthermore they highlight the increasing contribution that the life sciences sector makes to the Scottish economy."

Investment of the Year (2012) Award

Joint winners NuCana BioMed Limited, based in Edinburgh and GlaxoSmithKline, based in Irvine and Montrose

NuCana is in clinical studies with a new anti-cancer medicine that's been developed using its ground-breaking, patented ProTide technology.

The company secured the largest equity financing into a life sciences company in Scotland in over five years with £7 million of inward investment from leading venture capital companies in Europe and America alongside investment from the Scottish Investment Bank and Alida Capital International.

GlaxoSmithKline is to invest £100 million across its two Scottish sites and create around new 100 jobs including 65 high value jobs.

The investment will be used to make the Irvine site a centre of excellence for the production of antibiotics, as well as backing the development of respiratory medicines and vaccines in Montrose and increasing the firm's move to sustainable green energy production.